GLAXOSMITHKLINE has detailed the financial performance of its operations in Australia, including $406 million in 2017 revenue for GSK Consumer Healthcare.
The company said this division's profit before tax was $20 million, with the Panadol franchise continuing to be the leading pain relief brand, complemented by Voltaren for topical pain.
Acting gm ANZ of GSK Consumer Healthcare, Theresa Agnew, said despite a challenging year for the sector there were trends such as the ageing population and movement towards self-care which created opportunities for growth.
"Category and product innovation can help recognise these opportunities and improve health outcomes for consumers," she said.
GSK's pharmaceuticals and vaccines business reported $892m in revenue and profit of $22m, while ViiV Healthcare revenue was $90m, with a $1.4 million profit.
The above article was sent to subscribers in Pharmacy Daily's issue from 02 May 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 02 May 18
